IL6 and congenital rubella syndrome: Toxicity management strategies for CRS and ICANS in oncology may need adaptation for AID, relying on supportive care, tocilizumab, and corticosteroids, and Anti-CD19 CAR-T–driven rises in IL-6, IL-10, and IFN-γ promote perforin/gasdermin release that amplifies tissue damage and sHLH/MAS and CRS (122–124).